Levonorgestrel/Ethinylestradiol Focus

Levonorgestrel/Ethinylestradiol, the active ingredient in Levonorgestrel/Ethinylestradiol Focus, is a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy by inhibiting ovulation and altering cervical mucus, supporting endometrial changes in women of reproductive age.

GNH USA supplies Levonorgestrel/Ethinylestradiol Focus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with full EU market authorization and quality‑assured manufacturing, and a commitment to reliable delivery across global supply chains.

Levonorgestrel/Ethinylestradiol is a combined oral contraceptive used to prevent unintended pregnancy and manage hormone‑related menstrual conditions.

- Contraception: provides reliable prevention of pregnancy for women of childbearing potential. - Menstrual cycle regulation: helps achieve more predictable bleeding patterns and reduces menstrual irregularities. - Acne treatment: decreases androgen‑driven skin lesions in women requiring hormonal regulation.

Levonorgestrel/Ethinylestradiol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset, often transient. - Breast tenderness: temporary swelling or discomfort. - Headache: mild to moderate intensity. - Spotting between periods: irregular light bleeding. - Weight gain: modest increase in body weight. - Mood changes: irritability or emotional fluctuations.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to lung arteries. - Stroke: cerebrovascular accident due to clot or hemorrhage. - Myocardial infarction: heart attack risk, especially in smokers. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver tumor: rare hepatic adenoma development.

Before prescribing Levonorgestrel/Ethinylestradiol, clinicians should evaluate several safety considerations.

- Smoking: avoid use in women over 35 who smoke due to increased thrombotic risk. - History of thromboembolism: contraindicated in patients with prior deep vein thrombosis or